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Introduction {#sec005}
============

Anaemia affects approximately a third of the world's population and substantially reduces the disability- adjusted life years worldwide \[[@pone.0218694.ref001]\]. Iron deficiency contributes to development of anaemia and is diagnosed in more than half of all anaemic persons \[[@pone.0218694.ref002]\]. Consequently, iron supplements remain the backbone of prevention and treatment protocols for anaemia.

Anaemia has an extensive list of potential causes. In sub-Saharan Africa, where this condition is most common, its aetiology is even more complex and its investigation requires a multifactorial approach \[[@pone.0218694.ref003], [@pone.0218694.ref004]\]. HIV may cause anaemia by its direct effect on BM cells, but can also affect other aetiological factors including opportunistic viral, bacterial and parasitic infections, drugs such as zidovudine and co-trimoxazole, micronutrient deficiencies and neoplastic diseases \[[@pone.0218694.ref005], [@pone.0218694.ref006]\]. The exact role of iron deficiency, as one of the few preventable and treatable causes of anaemia, remains unclear due to its diagnostic challenges in HIV-infected patients in low resource settings \[[@pone.0218694.ref003], [@pone.0218694.ref004], [@pone.0218694.ref007]\]. However iron supplementation has been shown to be a risk factor for infections in areas of high infectious burden \[[@pone.0218694.ref008], [@pone.0218694.ref009]\]. Peripheral blood markers for iron deficiency, including erythrocyte indices, serum iron, ferritin, and soluble transferrin receptor (sTfR), have been evaluated but their accuracy is often negatively affected by inflammatory states, and renal and liver conditions, which are common in both the African and HIV-infected populations \[[@pone.0218694.ref010]--[@pone.0218694.ref013]\]. Previous studies therefore concluded that peripheral blood markers of iron status, such as ferritin, might not be reliable without a correction for inflammation \[[@pone.0218694.ref014], [@pone.0218694.ref015]\].

The evaluation of iron in the bone marrow is considered the 'gold standard' to diagnose iron deficiency, but bone marrow sampling is invasive and requires skilled staff for sampling and interpretation, which is challenging in low resource settings. Moreover, for large-scale use, a reliable peripheral blood marker to predict bone marrow iron deficiency (BM-ID) is needed to replace bone-marrow biopsy.

Hepcidin is a relatively new marker, which regulates iron absorption from the gastrointestinal tract and iron release from stores, both of which are important pathways controlling the availability of iron for incorporation in the erythrocyte precursors \[[@pone.0218694.ref016]\]. Increases of iron plasma levels stimulate the production of hepcidin, which blocks further iron absorption from the gastrointestinal tract and release of stored iron. In situations where erythropoietin demand and/or hypoxia are present (as in severe anaemia), hepcidin levels are decreased \[[@pone.0218694.ref017]--[@pone.0218694.ref019]\]. However, hepcidin is also upregulated by inflammation which may limit its use in settings where infections are common \[[@pone.0218694.ref020]\]. Hepcidin may have potential to guide iron therapy in severely anaemic children because in this population there is diminished up regulation of hepcidin in inflammation and iron deficiency due to an increase in erythropoietin \[[@pone.0218694.ref017]\]. It is therefore important to explore the possible role of hepcidin as a useful marker in guiding iron therapy in severely anaemic adults.

We investigated the prevalence of BM-ID in HIV-infected Malawian adult patients with severe anaemia. We further evaluated the accuracy of peripheral blood markers, as well of hepcidin to identify BM-ID in this population.

Methods {#sec006}
=======

From February 2010 to March 2011, all adults admitted to the Department of Internal Medicine of the Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi with a diagnosis of severe anaemia and HIV infection were approached for informed consent and study enrolment. This study was a sub-study of a larger observational cohort study (n = 199) of severely anaemic (haemoglobin ≤ 70 g/l) HIV-infected patients. Bone marrow sampling was performed if the patient consented and was clinically stable. This sub-study comprises 73 (37%) of the patients in the main study since for these patients BM samples of adequate quality were available.

Laboratory assays and blood markers {#sec007}
-----------------------------------

Haemoglobin concentration was measured on admission using the HemoCue B-Haemoglobin analyser (HemoCue, Ängelholm, Sweden) to screen patients for eligibility. After informed consent a venous blood sample was collected and bone marrow sample taken from the iliac crest. All blood samples were analysed within 24 hours of collection or stored at -80°C. Haemoglobin and red cell indices (MCV, MCH and MCHC) were determined using an automated haematology analyser (Beckman Coulter, Durban, South Africa). CD4-cell counts were assessed using BD FACS Count (BD Biosciences, San Jose, CA, USA). Transferrin, iron, ferritin, folate and vitamin B12 were analysed on Modular P800 and Monular Analytic E170 systems (Roche Diagnostics, Switzerland). Soluble transferrin receptor (sTfR) levels were measured using ELISA (Ramco Laboratories, TX, USA). Commonly used ratios to define iron deficiency were calculated including the sTfR index: sTfR (mg/L) divided by log ferritin (ug/L); and the 'sTfR ratio': sTfR (mg/L) x1000/ ferritin (ug/L) level \[[@pone.0218694.ref021]\]. International accepted cut-offs were applied. No international cut-offs have been defined for sTFR or for the sTFR index so we tested several previously used cut-offs. For sTfR we used 2.7 mg/l, 3.6 mg/l and 8.3 mg/l and for the sTfR index 1.8, 2.2 and 2.8 repectively \[[@pone.0218694.ref021]--[@pone.0218694.ref023]\].

Serum hepcidin-25 measurements were performed between December 2012 and January 2013 (Testing lab: [Hepcidinanalysis.com](http://Hepcidinanalysis.com), Nijmegen, The Netherlands) by a combination of weak cation exchange chromatography and time-of-flight mass spectrometry (WCX-TOF MS) using synthetic hepcidin-24 as internal standard \[[@pone.0218694.ref024]--[@pone.0218694.ref026]\]. Peptide spectra were generated on a Microflex LT matrix-enhanced laser desorption/ionisation TOF MS platform (Bruker Daltonics, Bremen, Germany). Hepcidin concentrations are expressed as nanogram per millilitre (ng/ml). The lower limit of detection of this method was 0.5 ng/ml \[[@pone.0218694.ref025]\].

BM-ID {#sec008}
-----

Bone marrow aspirate samples were spread onto slides and trephine biopsies were fixed, decalcified and embedded in paraffin wax \[[@pone.0218694.ref027], [@pone.0218694.ref028]\]. Bone marrow samples were sent to the Haematology Pathology Referral Centre at the Royal Liverpool University Hospital, Liverpool UK, for analysis. Sections of the trephine blocks were stained with Perls' Prussian Blue to detect iron stores \[[@pone.0218694.ref028]\]. Intracellular iron in bone marrow trephine blocks was graded using the Stuart-Smith scale, which classifies the iron content of bone marrow into six grades (0--6). For bone marrow smears, iron was graded using Gale's grading (0--4). Iron deficiency was defined as no visible or severely reduced iron particles in reticulum cells under high power magnification; grade 0--1 on both scales \[[@pone.0218694.ref029], [@pone.0218694.ref030]\]. The reviewing pathologist was only provided with the patient's identification number and was not aware of the clinical condition of the patient when reviewing the bone marrow.

Infections {#sec009}
----------

HIV infection was confirmed using two point-of-care antibody tests (Unigold^®^ and Determine^®^). Different types and severity of on-going and potential infections were evaluated including; HIV: CD4 counts ≤200 cells/mm^3^ and/or viral load \>1000 copies/ml. Malaria: presence of malaria parasites in a thick blood film assessed by light microscopy. Tuberculosis (TB) defined as one or more of the following: a) positive sputum culture; b) chest X-ray with signs of pulmonary tuberculosis and/or; c) on-going TB treatment at time of enrolment; d) clinical diagnosis based on generalized lymphadenopathy and/or night sweats \> 30 days with unknown origin; e) caseating granulomata in the bone marrow trephine. Bacteraemia was defined as a blood culture that grew a potential pathogen including streptococcus, enterococcus and micrococcus species, non-Typhoid Salmonella and Klebsiella pneumonia. Viral infections including parvo-B19, cytomegalovirus (CMV) and Epstein-Barr virus (EBV) were evaluated by PCR and defined as positive by viral load \>100 copies/ml.

Ethics {#sec010}
------

The Research Ethics Committee of the College of Medicine, University of Malawi (P.09.09.824) and the Research Ethics Committee of Liverpool School of Tropical Medicine (research protocol 09.64) approved the study. The purpose of the study was explained to the patients in the local language (Chichewa), and written informed consent was obtained before inclusion into the study.

Statistics {#sec011}
----------

The data were analysed using Stata (version 12) (STATA Corp. LP, Texas, TX, USA). Baseline characteristics were compared between BM-ID and non-iron-deficient patients using Chi-square test (dichotomous data) or t-test (continuous) or Pearson Chi-square test (continuous not normally distributed). To assess any confounding factors, hepcidin concentrations were evaluated by gender, HIV disease progression, the use of ART at enrolment, and TB infection (Pearson Chi-square test). The p-values reported are two-sided, and a level of p\<0.05 was interpreted as significant. The accuracy of the different peripheral blood markers, including hepcidin, to discriminate BM-ID was evaluated by receiver operating characteristics curves (ROC)\[[@pone.0218694.ref031]\]. Corresponding areas under the curve (AUC^ROC^) were created. AUC^ROC^ measures the two-dimensional area underneath the ROC curve and provides a summative measure of performance across all possible classification thresholds \[[@pone.0218694.ref032]\]. The AUC^ROC^ \<0.70 is considered to be of low diagnostic accuracy; AUC^ROC^ of 0.70--0.90 as moderately accurate and a AUC^ROC^ ≥0.90, of high diagnostic accuracy \[[@pone.0218694.ref033]\]. Sensitivity and specificity were calculated for predefined internationally accepted cut-offs \[[@pone.0218694.ref010], [@pone.0218694.ref021], [@pone.0218694.ref023], [@pone.0218694.ref034]\]. For hepcidin the best cut-off value for diagnosing BM-ID was determined using ROC-curve analyses with the Youden index (maximum (sensitivity + specificity-- 1))\[[@pone.0218694.ref032]\]. As gender differences are known to occur for hepcidin \[[@pone.0218694.ref030]\], hepcidin results were disaggregated by gender.

Results {#sec012}
=======

Of the 73 HIV-infected adults in this study, a total of 45 (61.6%) had severe anaemia (Hb 50-\<70g/dL) and 28 (38.4%) had very severe anaemia (Hb\<50g/dL). The mean patient age was 33.7 (SD 8.7) years, and 43 (58.9%) patients were female. A CD4 count ≤ 200 cells/mm^3^ was present in 31/56 (55.4%) and a viral load \>1000 copies/ml was present in 57/76 (75.0%) of patients. A total of 34/73 (46.6%) patients were on anti-retroviral ART treatment at enrolment, of which most were on first line treatment at time of the study (Efavirenz, Lamivudine, Tenofovir). The most common infections in this population were tuberculosis (39/73; 53.4%) and EBV (30/45; 66.7%). All baseline characteristics are shown in [Table 1](#pone.0218694.t001){ref-type="table"}.

10.1371/journal.pone.0218694.t001

###### Baseline characteristics in this population of severely anaemic HIV patients, stratified according to bone marrow iron deficiency (BM-ID).

![](pone.0218694.t001){#pone.0218694.t001g}

  Characteristic                                              Overall             Non BM-ID           BM-ID
  ----------------------------------------------------------- ------------------- ------------------- -------------------
  Age, years (mean, SD)                                       33.7 (8.7)          32.7 (8.6)          34.7 (8.9)
  Gender (female) (%)                                         43/73 (58.9%)       19/38 (50.0%)       24/35 (68.6%)
  **Haematology and iron markers**                                                                    
  Very severe anaemia (Hb≤ 50g/l) (%)                         28/73 (38.4%)       13/38 (34.2%)       15/35 (42.9%)
  Haemoglobin(Hb)(g/l)(median, IQR)                           56.0 (43.0--63.0)   58.5 (45.0--64.0)   54.0 (36.0--63.0)
  MCV (fl) (median, IQR)                                      85.8 (79.4--98.1)   87.3 (79.6--99.0)   83.5 (79.1--94.7)
  MCH (pg/cells) (mean, SD)                                   29.0 (5.9)          23.6 (6.1)          26.3 (5.5)
  Serum iron (umol/l) (median, IQR)                           5.1 (3.3--11.1)     4.7 (3.0--7.9)      5.6 (3.8--22.2)
  Ferritin (ug/dL) (median, IQR)                              87.2(49.6--100.0)   87.1 (50.1--97.1)   87.9(36.0--100.0)
  sTfR receptor (mg/l) (median, IQR)                          2.9(1.6--3.7)       2.8(1.7--3.7)       3.0(1.2--3.9)
  sTfR index (median, IQR)                                    1.6 (0.8--2.2)      1.5 (0.9--2.1)      1.6 (0.6--2.6)
  sTfR Ratio (median, IQR)                                    35.1 (17.5--69.3)   33.2 (21.3--61.9)   36.6(11.5--79.6)
  Hepcidin (ng/ml) (median, IQR)                              7.3(3.3--13.3)      9.2 (4.9--13.2)     5.1 (3.1--13.7)
  **HIV disease and treatment**                                                                       
  ART at enrolment (%)                                        34/73 (46.6%)       20/38 (52.6%)       14/35 (40.0%)
  CD4 count ≤ 200 cells/mm^3^                                 31/56 (55.4%)       15/28 (53.6%)       14/25(56.0%)
  Viral load \>1000 copies/ml                                 57/76 (75.0%)       25/38 (65.8%)       30/35 (85.7%)
  **Infection(s)**                                                                                    
  Bacteraemia [^3^](#t001fn004){ref-type="table-fn"}          12/73 (16.4%)       6/38 (15.8%)        6/35 (17.1%)
  Malaria[^4^](#t001fn005){ref-type="table-fn"}               3/63 (4.7%)         2/32 (6.3%)         1/31 (3.2%)
  Tuberculosis[^5^](#t001fn006){ref-type="table-fn"}          39/73 (53.4%)       20/38 (52.6%)       19/35 (54.3%)
  Epstein-Barr virus [^6^](#t001fn007){ref-type="table-fn"}   30/45 (66.7%)       19/26 (73.1%)       11/19 (57.9%)
  Cytomegalovirus [^6^](#t001fn007){ref-type="table-fn"}      18/54 (33.3%)       11/28 (39.3%)       7/26 (26.9%)
  Parvo-B19 virus[^6^](#t001fn007){ref-type="table-fn"}       1/59 (1.7%)         0/27 (-)            1/32 (3.1%)
  **Nutritional status**                                                                              
  Underweight (BMI \< 18.5) (%)                               22/49 (44.9%)       8/24 (33.3%)        14/25 (56.0%)

All tested p-values were \> 0.1. Abbreviations: ART: antiretroviral therapy. BMI: Body mass index. TB: Tuberculosis.

^1^ First line ART include combination of Stavudine (d4T), Lamivudine (3Tc) and Nevirapine (NVP) \[[@pone.0218694.ref035]\].

^2^ Advanced HIV disease including a CD4 count ≤ 200 cells/mm^3^ and/or viral load \> 1000 copies/ml.

^3^Bacteraemia; a blood culture with a potential pathogen including streptococcus (41.7%; 5/12), enterococcus (16.7%;2/12) and non-Typhoid Salmonella (16.7%;2/12).

^4^Malaria: presence of malaria parasites on a thick blood film.

^5^Tuberculosis (TB): one or more of the following present: a) positive sputum culture, b) chest X-ray with signs of pulmonary tuberculosis and/or c) on-going TB treatment at time of enrolment d) clinical diagnosis by local doctor including unknown generalized lymphadenopathy and/or night sweats \> 30 days with unknown origin e) caseating granulomata in the bone marrow trephine.

^6^ Epstein-Barr, cytomegalo- and parvo-B19 virus infection are diagnosed by a viral load of 1000 copies/ml. Abbreviations: MCV; mean cellular volume, MCH; mean corpuscular haemoglobin, s-TfR: Soluble transferrin receptor, TfR-index (sTfR(mg/L) /Log ferritin(ug/L)), TfR Ratio (sTrR(mg/L))x1000/ferritin(ug/L)).

BMI-ID and blood markers {#sec013}
------------------------

BM-ID was seen among 35 (48.0%) of the patients ([Table 1](#pone.0218694.t001){ref-type="table"}). The performances of the peripheral blood markers to diagnose BM-ID are displayed in [Table 2](#pone.0218694.t002){ref-type="table"}. All markers displayed low diagnostic accuracy (AUC^ROC^\< 0.7). MCV had the highest AUC^ROC^ value of the common peripheral blood markers (0.545), the sensitivity and specificity using the common cut off of 83fL were 42% and 67% respectively. The use of hepcidin to detect BM-ID resulted in an AUC^ROC^ 0.593. We stratified the analysis for hepcidin according to gender; the AUC^ROC^ for men and women was 0.767 and 0.490 respectively. The optimal hepcidin concentration for the detection of BM-ID was ≤7 ng/ml (sensitivity 67%, specificity 67%). In males the optimum cut off was ≤6 ng/ml (sensitivity 80%; specificity 78%) whilst for women this was ≤7 ng/ml (sensitivity 60%; specificity 61%, [Fig 1](#pone.0218694.g001){ref-type="fig"}). The hepcidin concentration did not differ significantly by gender (p = 0.831), HIV disease progression (p = 0.819), the use of ART at enrolment (p = 0.616), and TB infection (p = 0.590) in a univariate analysis. Hepcidin levels were negatively correlated with sTfR receptor (mg/l)^3^; Beta -0.62, p = 0.041) and positive towards sTfR index (sTfR(mg/L) /Log ferritin(ug/L)); Beta 8.3, p-value 0.001), [S1 Table](#pone.0218694.s002){ref-type="supplementary-material"}.

![Hepcidin (ng/ml) ROC curve by gender with optimal cut-off.\
The best cut-off value for diagnosing BM-ID, [Table 1](#pone.0218694.t001){ref-type="table"}, was determined by the Youden index (maximum (sensitivity + specificity −1)) in the ROC-curve (32). Hepcidin overall; AUC^ROC^ 0.593, optimal cut-off ≤7 ng/ml (sensitivity 67% and specificity 67%). Hepcidin in males; AUC^ROC^ 0.767 optimal cut-off ≤6 ng/ml (sensitivity 80%; specificity 78%). Hepcidin in females 0.490 optimal cut-off ≤7 ng/ml (sensitivity 60% and specificity 61%. Abbreviations: AUC^ROC^: area under curve of receiver operating characteristic.](pone.0218694.g001){#pone.0218694.g001}

10.1371/journal.pone.0218694.t002

###### Accuracy of peripheral blood markers to detect bone marrow iron deficiency (gold standard).

![](pone.0218694.t002){#pone.0218694.t002g}

  Potential markers                                            AUC^ROC^   95%-CI         Cut-off   Sensitivity   95%-CI        Specificity   95%-CI
  ------------------------------------------------------------ ---------- -------------- --------- ------------- ------------- ------------- -------------
  MCV (fl)[^1^](#t002fn002){ref-type="table-fn"}               0.545      0.404--0.685   ≤83       42%           25.2--58.8%   67%           51.0--83.0%
  MCH (pg/cells) [^1^](#t002fn002){ref-type="table-fn"}        0.365      0.230--0.499   ≤27       52%           35.2--69.0%   29%           13.7--44.3%
  Serum iron (μmol/l) [^1^](#t002fn002){ref-type="table-fn"}   0.368      0.239--0.498   ≤ 10      60%           43.8--76.2%   18%           5.8--30.2%
  Ferritin (μg/l) [^1^](#t002fn002){ref-type="table-fn"}       0.441      0.293--0.588   ≤30       13%           1.0--25.0%    88%           76.7--99.3%
                                                                                         ≤70       30%           13.6--46.4%   66%           49.6--82.4%
  sTfR receptor (mg/l)[^3^](#t002fn002){ref-type="table-fn"}   0.522      0.378--0.667    ≥2.7     58%           40.6--73.1%   56%           39.3--72.7%
                                                                                          ≥3.6     32%           15.6--48.2%   76%           61.6--99.4%
                                                                                         ≥8.3      3%            0--9.0%       100%          100%
  sTfR index [^4^](#t002fn002){ref-type="table-fn"}            0.523      0.375--0.672    ≥1.8     47%           29.1--64.9%   67%           46.3--79.7%
                                                                                          ≥2.2     27%           11.1--42.9%   75%           60.0--90.0%
                                                                                          ≥2.8     20%           5.7--34.3%    81%           67.4--94.6%
  sTfR Ratio [^4^](#t002fn002){ref-type="table-fn"}            0.508      0.359--0.656    ≥100     17%           0--23.4%      91%           71.1--90.9%
  Hepcidin^5^ overall                                          0.593      0.447--0.739   7.0       67%           50.2--83.8    67%           51.6--82.4
  Hepcidin^5^ Males                                            0.767      0.567--0.960   6.0       80%           55.2--100.0   78%           52.9--91.1
  Hepcidin^5^ Females                                          0.490      0.298--0.682   7.0       60%           38.5--81.5    61%           38.5--83.5

Abbreviations: AUC: area under curve of receiver operating characteristic (ROC), where 0.5 would be expected by chance and 1 denotes a test with perfect diagnostic accuracy. 95%-CI: 95% confidence interval. MCV; mean cellular volume, MCH; mean corpuscular haemoglobin, sTfR: Soluble transferrin receptor, sTfR index (sTfR(mg/L) /Log ferritin(ug/L)), sTfR Ratio (sTrR(mg/L))x1000/ferritin(ug/L)).

^1^ \[[@pone.0218694.ref029]\] ^2^ \[[@pone.0218694.ref011]\] ^3^ \[[@pone.0218694.ref022]\] ^4^\[[@pone.0218694.ref021], [@pone.0218694.ref023]\]. ^4^ Hepcidin results are shown based on outcome of [Fig 1](#pone.0218694.g001){ref-type="fig"}. The best cut-off value for diagnosing BM-ID was determined by the Youden index (maximum (sensitivity + specificity −1)) in the ROC-curve \[[@pone.0218694.ref032]\].

Discussion {#sec014}
==========

In this study on hepcidin and conventional markers to detect BM-ID in severely anaemic HIV-infected patients in Malawi, we found that BM-ID was present in almost half of our patients. In this study, the first evaluating hepcidin as a marker for BM-ID among severely anaemic HIV-infected adults in this setting, we found all tested markers performed suboptimally in detecting BM-ID. Hepcidin was the best performing marker but had a suboptimal accuracy (AUC^ROC^ 0.593), which was less pronounced in males (AUC^ROC^ 0.767). Hepcidin and (standardized) identified cut-offs may therefore have some use as a marker to define BM-ID and to guide iron supplementation in HIV-infected patients in resource limited settings such as Malawi. Intervention studies, using hepcidin as a marker in males and females, should be performed to assess feasibility and effect of such a test.

BM-ID was highly prevalent among our population of HIV-infected and severely anaemic patients. It was higher than in previous reports on similar populations that were published in the pre-ART era when BM-ID was reported to be 18%-25% in severely anaemic HIV patients \[[@pone.0218694.ref010], [@pone.0218694.ref036]\]. The high prevalence of BM-ID in our patients may be explained by the effect of ART. Previous reports on HIV-associated anaemia before 2010 included patients who were mostly ART naïve, and advanced HIV disease and/or severe immune suppression were common \[[@pone.0218694.ref010]\]. Although VL above 1000 copies/ml (75%) and CD4 counts below 200 cells/ml were (55.4%) still common in our study population, median CD4 counts (325 cells/mm^3^) were much higher than in the previous reports (median 67 cells/ml) \[[@pone.0218694.ref004], [@pone.0218694.ref010]\]. Initiation of ART aims to stop HIV disease progression, promote immune reconstitution and reduce the risk of (opportunistic) diseases. These effects may be reflected in our cohort, and have likely changed the aetiology of severe anaemia among HIV-infected patients compared to older, pre-ART studies. In our group of HIV-infected patients, who probably have less immunosuppression, the aetiology of severely anaemic may be more similar to the aetiology in non-HIV infected patients. The BM-ID prevalence of 48% is comparable to previous findings among HIV-uninfected African populations with severe anaemia, which supports this hypothesis \[[@pone.0218694.ref010]\]. Our data need to be confirmed in the on-going 'treat all' ART era but they have potential to impact on preventive and curative policies concerning iron supplementation in severely anaemic HIV-infected patients. Irrespective of the cause, the role of iron supplementation to prevent and treat severe anaemia appears to have gained importance.

Our results concerning the accuracy of peripheral blood markers to detect BM iron deficiency indicate that it is not easy to reliably detect those with deficient BM iron stores, which corroborates previous studies \[[@pone.0218694.ref010], [@pone.0218694.ref011]\]. Hepcidin did perform slightly better than conventional markers, but was still sub-optimal especially in females. Additionally, hepcidin is a key player in the absorption of iron and thus may be used to not only identify patients needing iron but also may predict iron supplementation, response, safety and timing. Hepcidin as a possible marker for BM-ID has not been evaluated before in this population of severely anaemic HIV-infected adults in Africa. It is not surprising that hepcidin is not an optimal marker for BM-ID as hepcidin levels are affected by inflammation which is common among HIV-infected patients, especially those living in resource-limited settings \[[@pone.0218694.ref037]--[@pone.0218694.ref039]\]. For example, when hepcidin levels are high, the absorption of dietary iron and release of macrophage iron to serum are blocked, resulting in a relative hypoferremia and an increase in iron in the macrophages; this is thought to be a protection mechanism against infections. Consequently during malaria or TB infection, or immune deficiency with low CD4 counts, hepcidin levels are increased \[[@pone.0218694.ref038], [@pone.0218694.ref039]\]. Among children in Malawi, including children with HIV, we have previously reported low hepcidin levels \[[@pone.0218694.ref017]\]. As low hepcidin levels are likely to be due to diminished up-regulation of hepcidin in response to inflammation and iron deficiency (due to an increase of erythropoietin) in this population, hepcidin was suggested as a possible useful marker in guiding iron therapy \[[@pone.0218694.ref017]\]. However, low hepcidin levels during severe anaemia is not exclusive for an absence of inflammation other potential involvement of hepcidin suppressive signals during severe anaemia, as for example an ineffective erythropoiesis should also be considered.

Worldwide hepcidin concentrations are measured by various methods, which differ considerably in absolute hepcidin concentrations \[[@pone.0218694.ref040]\]. Recently, secondary hepcidin reference material, that has been value-assigned by a primary reference material, has become available \[[@pone.0218694.ref041]\]. Standardization in February 2019 of a similar hepcidin assay to the one we used in 2012--13, resulted in only a 5.4% increase of hepcidin concentrations (C. Laarakker and D. Swinkels unpublished data) \[[@pone.0218694.ref042]\]. For our study population, our results provide a first and rough estimate for hepcidin cut-off points that are comparable to other assays that have been standardized using the reference material. However, for formal universal use of these cut-off points these values should be confirmed by studies that directly measure samples with a standardized hepcidin method. Additionally, hepcidin optimal cut-offs were more sensitive and lower for men compared to women and age and gender differences in hepcidin concentrations are known. For the age group of our study population (mean 30--35 years) normal hepcidin concentrations have been reported to be higher in men than women \[[@pone.0218694.ref041], [@pone.0218694.ref043]\]. However this reference data is based on European populations: hepcidin reference levels are not known for African populations. These age, sex and potential geographical differences make any direct comparisons challenging. Our results therefore need to be confirmed with studies that use the recently standardized hepcidin method.

Iron deficiency is treatable and preventable, however supplementation has been associated with an increased number of severe infections, including malaria, which, especially in an immune compromised population, may be dangerous \[[@pone.0218694.ref009], [@pone.0218694.ref044]\]. Moreover recently (2019) it has been shown that iron supplementation in a HIV population is related to increased mortality \[[@pone.0218694.ref045]\]. Therefore a reliable diagnosis of iron deficiency in HIV-infected patients is important, as supplementation could put the patients at risk. Our study underlined that the currently used peripheral blood markers for iron deficiency performed poorly. This is a common problem especially in resource limiting settings where poor performance has been related to inflammatory conditions which are particularly frequent African HIV-infected patients \[[@pone.0218694.ref010], [@pone.0218694.ref011]\]. Some of the markers tested, such as sTfR concentrations, alone or in combination with other markers, may better reflect iron stores \[[@pone.0218694.ref046]\] irrespective of inflammation \[[@pone.0218694.ref047]\]. Although sTfR had a poor AUC^ROC^ it did have a better sensitivity than hepcidin and thus may be used to screen for iron deficiency. Overall sTfR levels in our population were low compared to other studies \[[@pone.0218694.ref048]\]. This may reflect the high prevalence of inflammation and end-stage HIV disease in our population, which are both associated with low sTfR levels \[[@pone.0218694.ref038]\]. The method we used for sTfR was feasible in the Malawian setting but other studies have used different methods for sTFR so our results may not be directly comparable to results from other studies. We have therefore evaluated several previously published cut-offs for sTFR and used AUC-ROC curves to try and identify potential improved cut-offs. Reasons for the poor performances of sTfR in our population may be the lack of clear cut-offs, as suggested by other studies \[[@pone.0218694.ref010]\], and the fact that sTfR is also influenced by erythropoietin, which may play an important role in severe HIV-associated anaemia \[[@pone.0218694.ref038]\]. The best, though still suboptimal, conventional peripheral blood marker for iron deficiency, was MCV. Microcytosis is commonly used as a screening test for iron deficiency \[[@pone.0218694.ref034], [@pone.0218694.ref049],[@pone.0218694.ref050]\]; however, MCV has not been found to be an accurate predictor of BM-ID \[[@pone.0218694.ref010], [@pone.0218694.ref011], [@pone.0218694.ref048]\]. Our findings confirm this as MCV did not have a high sensitivity or specificity and the AUC^ROC^ was of low diagnostic value.

Our study has several shortcomings. Firstly, bone marrow testing was only performed in a subset of patients, which may have introduced a sampling bias. Reasons for not taking bone marrow included a severe clinical condition of the patient, or patients not consenting to this aspect of the study. However, it is one of the largest studies of one marrow iron deficiency in African HIV-infected patients to date. Secondly, our study was performed in 2010 when ART was provided according to the national and hospital guidelines. Accordingly, ART could only be started in the outpatient ART clinic after discharge from hospital. Currently ART is started much earlier in the course of HIV infection so our study patients are likely to have had more advanced HIV disease than current patients. Other than screening for pathogens, we did not determine inflammatory markers such as CRP in our patients. Nevertheless, this is the first study combining bone marrow data with a large set of peripheral blood markers, including hepcidin, in a group of HIV-infected severely anaemic African patients. Hepcidin may be influenced by multiple interacting stimuli in this patient population including, iron deficiency, anaemia, hypoxia and inflammation. We found an inverse association between hepcidin and sTfR, which may indicate that inflammation was an important factor in our population. Low hepcidin values in our patients indicate that iron stores are deficient and suggest that iron supplements will likely be absorbed. However, the effectiveness and safety should be evaluated in a prospective trial design in this population. We believe our study provides valuable information for clinicians who care for HIV-infected patients with severe anaemia in Malawi and other resource-limited settings.

Conclusion {#sec015}
==========

Bone marrow iron deficiency was present in almost half of severely anaemic HIV-infected adults. This is higher than comparative data from the pre-ART era, and underlines the potential importance of preventive and therapeutic iron supplementation to reduce the problem of severe anaemia in HIV-infected patients. Detection and safe treatment of BM-ID is hampered by a lack of informative markers of iron deficiency. Although suboptimal, and not routinely available in resource-poor settings, hepcidin was found to be the most accurate marker of those we evaluated, and may be helpful to guide and predict the effect of iron supplementation. Precise knowledge of an individual's iron status is important because of the potential risk of increased infection risk due to iron supplementation, so the effectiveness of using hepcidin should be evaluated in future intervention studies.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: General comments:

Iron deficiency is a prominent cause of anaemia yet its assessment can be challenging in the context of infection/inflammation, since many biochemical indicators of iron are confounded by inflammation or other factors. Bone marrow iron staining is considered a gold standard means of identifying total body iron deficiency -- however, it is invasive and low throughput.

This present manuscript presents bone marrow iron staining, combined with peripheral iron status biomarker data, from a subset of severely anaemic HIV-infected patients who were enrolled into a study of HIV-associated anaemia; data on co-existing morbidities, potentially contributing to anaemia, are presented in a manuscript submitted in parallel with the present paper. It is relatively unusual to have an analysis of bone marrow iron from vulnerable populations such as this,giving strength to this study. The authors perform diagnostic test analysis for the ability a range of iron-related biomarkers to identify bone marrow iron deficiency. Of the biomarkers tested, hepcidin gave the highest ROC-AUC, but all tests performed poorly, highlighting the difficulty of reliably assessing iron status in this complex clinical setting -- patients with advanced HIV infection. There was a clear discrepancy in the performance of hepcidin in males and females, with hepcidin performing moderately well in males.

Similar studies from the same location have previously been published, e.g. Lewis et al, Trans R Soc Trop Med Hyg. 2007 -- this analysis was not restricted to HIV infection (but did consider HIV infection within analysis) and did not include hepcidin. The conclusions presented in the current manuscript are broadly similar to those previously presented, i.e. that iron deficiency diagnosis is challenging to diagnose during HIV infection without bone marrow iron staining.

A major focus of the manuscript (e.g. see title) is hepcidin. It is important to increase understanding of hepcidin across different clinical settings in order to aid its interpretation. There is a good opportunity here to investigate how hepcidin associates with other iron markers including BM-ID in the context of severe HIV-associated anaemia -- where infection, inflammation, low iron status and erythroid demand may co-exist. The authors could perform univariate and multivariate analyses accordingly -- in my view this would enhance the interest level of the paper, and the authors should consider performing such investigations.

Specific points:

1\. Data availability: the authors state that raw data will be available within the manuscript or supplementary information -- it's not clear whether this has been provided yet. It would be helpful to refer to this within the manuscript.

2\. Ethics Statement: the study does involve human participants -- the authors should therefore add the ethics statement where required.

3\. Title: The short title is actually more informative than the main title -- suggest using this or similar.

4\. Abstract: Line 47 -- although hepcidin and MCV performed best, these are still low AUC-ROC indicating poor performance -- this should be made clear. (e.g. "Although hepcidin and MCV gave the highest AUC-ROC....., all markers performed poorly in identifying BM-ID" or similar). Similar in line 52.

5\. Abstract: Lines 52-54 -- The final line of the conclusion is not fully supported by the data which finds hepcidin to perform poorly overall in identifying BM-ID, albeit slightly less poorly than the other markers (and with moderate performance in males). Furthermore, whether iron supplementation in such settings is curative is controversial (e.g. see recent publication Haider et al, Am J Trop Med Hyg, 2019). This conclusion should be softened, e.g. state that it still remains challenging to accurately assess iron status in HIV using peripheral blood markers / say further investigation of the potential of hepcidin should be performed, especially to confirm the discrepancies between males and females.

6\. Introduction: Line 62 -- the authors could also point out the risk of iron supplements in areas of high infectious burden (e.g. Sazawal et al, Lancet, 2006; Pasricha et al, BMJ, 2018).

7\. Introduction: Line 77 -- reference to the BRINDA work could also be useful here (e.g. Suchdev et al, AJCN, 2017)

8\. Introduction: Line 88 -- it is also essential also to discuss hepcidin suppression during erythropoietic demand or hypoxia (e.g. via erythroferrone), especially here where all patients in the study are severely anaemic. In this section, the authors could also cite other studies/contexts where hepcidin has been investigated as a possible diagnostic for iron deficiency (e.g. ref 34 (Jonker); Pasricha et al, STM, 2014; Pasricha et al, Haematologica, 2011)

9\. Methods: Line 115-119 -- sTfR definitions. Ref 16 shows that the Ramco assay is calibrated differently to other sTfR assays. It is essential to give further detail on the choice of cutoff -- the 3.6 mg/L cutoff in 16 is based on a different assay. Furthermore, it is hard to see where the 2.75 mg/L cutoff came from; similarly, the sTfR-index cutoffs are assay dependent. This should be clarified and analyses reperformed as necessary.

10\. Methods: BM-ID. Whether or not blinding was used should be described.

11\. Methods/Results: Were any inflammatory markers (e.g. CRP, AGP) assessed or could samples be reanalysed to add this data? These would aid the analysis and its interpretation. Additionally, if samples were still available, measuring erythroferrone (e.g. Intrinsic ELISA) would be very interesting.

12\. Results: Table 1 / Lines 201-203 -- hepcidin results are presented in ng/mL, yet LOD in methods is given in nmol/L -- the units should be synchronised.

13\. Results: Table 2 -- hepcidin data should be added to this table for completion - it is not particularly clear linked to Figure 1 (partly due to resolution issues).

14\. Discussion -- line 243/244 -- see point above on abstract-line 47. Suggest changing the emphasis to indicate that they are still generally poor performing tests in this setting -- this raises the question of its suitability for use in this setting.

15\. Discussion -- line 249-250: the authors should add supporting evidence from the literature that ART associates with iron-deficiency (specifically, not just anaemia).

16\. Discussion - line 264, 270, 308-311: attention is drawn to the recently published large study on anaemia and mortality in HAART-treated HIV in which iron supplements during HAART were associated with increased mortality (Haider et al, Am J Trop Med Hyg, 2019). It would be useful to draw this into the discussion.

17\. Discussion -- line 273: besides inflammation, the potential involvement of hepcidin suppressive signals during severe anaemia should also be considered (e.g. is there a negative association between hepcidin and sTfR concentrations).

Formatting / Spelling:

• Authors: "Dorine Swinkels" (not "Dorien")

• Methods -- Statistics: Line 165 -- sentence is unclear ("confounding was enhanced...")

• Line 299: "men" and "women"

• Reference 37: "Reference values..."

Reviewer \#2: I would like to thank the authors for submitting this article for publication. the etiology of severe anemia in HIV infected persons living in resource limited countries is a serious dilemma as iron supplementation could result in increased morbidity and mortality, and bone marrow evaluation is tedious and not always available. The findings of this study are important as to my knowledge no previous study in resource limited settings has evaluated the use of peripheral markers compared with bone marrow findings for detection of iron deficiency in HIV infected persons and this study provides valuable information for stake holders and program managers. before I recommend this study for publication, i would like the authors to address a few concerns.

Major comments:

1\. Hepcidin as a serological test to evaluate for iron deficiency is relatively expensive and not readily available compared to other more conventional tests such as complete blood counts (MCV, MCH), ferritin levels, serum iron and even soluble transferrin receptor. Given that hepcidin only marginally performed better than MCV in the AUCROC analysis (0.59 vs 0.55, both low diagnostic accuracy at \<0.7), will the authors strongly recommend this as the best possible peripheral test for evaluation of iron deficiency in HIV infected populations in resource limited settings with high levels of inflammation?

2\. It is interesting that the prevalence of BM iron deficiency is relatively high in this study population of HIV infected, severely anemic adults- 48%, similar to the non-HIV infected population and prevention and treatment of iron deficiency still plays a vital role in management of severely anemic HIV infected patients. Were there other potentially treatable causes of severe anemia noted by the authors? for example, from the baseline table, the percentage of the study population with high viral loads (\>1000 copies/ml) was very high at 75% and this could have also contributed significantly to anemia in this population.

3\. Iron supplementation has been found to increase the risk of malaria and other infectious diseases in Malawian HIV infected children from previous randomized controlled trials. Given that iron deficiency strongly contributes to the etiology of anemia in this study population of HIV infected adults, how do the authors suggest that this problem (found in nearly half of your study population) be addressed?

4\. stfr receptor had an AUC of 0.52 (low diagnostic accuracy) but a better sensitivity (71%) than hepcidin (67%) and (MCV 42%) from the findings of this study. would this not be a better screening tool for iron deficiency than hepicidin given the availability and cost? or are the authors going strictly by the AUC, which for both markers (hepcidin and stfr receptor) are equally poor?

Minor comments:

1\. Why are p values provided in table 1? are the authors trying to tell us that the iron markers, infection rates, HIV tests and nutritional status did not differ significantly in the BM-ID vs non BM-ID group?

2\. Could the authors offer further explanation as to why the hepicidin test performed better in males than females, with the test over 0.7 in males with sensitivity of 80% and sensitivity of 78% compared with females, with the AUC of \<0.5 with poorer sensitivity and specificity?

3\. Discussion, line 272, second sentence: \'it is not surprising that hepcidin remains from perfect as a marker for BM-ID" should be changed to 'it is not surprising that hepcidin remains far from perfect as a marker for BM-ID\'

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

4 Oct 2019

To: PLOS ONE Kostas Pantopoulos, PhD Academic Editor

Subject: Rebuttal letter resubmission Manuscript ID: PONE-D-19-15824

September 2019

Dear Kostas Pantopoulos,

We thank you for considering our manuscript titled; "Hepcidin and conventional markers to detect iron deficiency in severely anaemic HIV-infected patients in Malawi " for publication in your journal. We would like to highlight that we initially submitted two manuscripts back to back. The other manuscript titled; "Severe anaemia complicating HIV in Malawi; multiple co-existing aetiologies are associated with high mortality" (PONE-D-19-15827) has also been resubmitted. Please receive the suggested changes and answers considering the issues raised by the reviewer. In our reply we indicated the original text (with respective line and page numbers) and changes are underlined. As requested we have tracked change all changes made in the original manuscript.

At first we would like to comment on the requested update for the funding Statement and competing Interests with regard to our author Dorine Schwinkels and Hepcidinanalysis.com. The statement relating to the author role contributions is adjusted: Dorine W. Swinkels is an employee of Radboud UMC that offers high quality hepcidin measurements via Hepcidinanalysis.com at a fee for service basis. \'Hepcidinanalysis.com\' did not play any role in the study design, data collection. Thank you for the online change in the submission form on our behalf.

Major comments:

1\. Particular attention should be given on analysing hepcidin association with other iron markers. Accuracy of the title should be considered, while implications of the findings for treatment of iron deficiency in this patient population should be discussed.

• We appreciated this comment and adjusted the title: A possible role for hepcidin in the detection of iron deficiency in severely anaemic HIV-infected patients in Malawi

• Implications: we added a new line 353 (page 13): Hepcidin and (standardized) identified cut-offs are highly likely to be relevant as there is a need for a reliable marker to define BM-ID and to start iron supplementation among HIV-infected patients in resource limited settings such as Malawi. Intervention studies, using hepcidin as a marker in males and females, should be performed to assess feasibility and effect of such an intervention. In the meanwhile, as the MCV is commonly provided as part of routine full blood counts this marker may be of some use in resource-limited settings.

2 &3. General. Data availability: Have the authors made all data underlying the findings in their manuscript fully available? The author's state that raw data will be available within the manuscript or supplementary information -- it's not clear whether this has been provided yet. It would be helpful to refer to this within the manuscript. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements.

• We regret this comment and realised that the sentence was not additive and therefore deleted it. Line 298 page 13:

Therefore a direct comparison is challenging. At last an explanation(s) can be found in levels of infection or control of the HIV disease, which in our population was not different for woman and man (data not shown).

• All data was given within the manuscript. We did not explicitly ask for medical ethical permission to publish our database online. In case individual readers are interested in using anonymised data we can and will share our database or requested data, we have added this to the results section

• Methods were adjusted line 178 page 5; Additional raw data can be requested by contacting the corresponding author.

Ad reviewer 1:

4\. There is a good opportunity here to investigate how hepcidin associates with other iron markers including BM-ID in the context of severe HIV-associated anaemia -- where infection, inflammation, low iron status and erythroid demand may co-exist. The authors could perform univariate and multivariate analyses accordingly -- in my view this would enhance the interest level of the paper, and the authors should consider performing such investigations.

• We agree that investigating the associations of hepcidin in this population is of interest to better understand factors regulating hepcidin in these patients who may have competetive stimuli. We have added the requested data concerning the associations between hepcidin and iron markers. As the aim of this paper was to assess the performance of peripheral iron marker in our population and not unravelling the competitive stimuli of hepcidin metabolism, which is a paper on itself, we have restricted the analysis to a univariate linear regression analysis. The results of this linear regression analysis are presented in table S1 and displayed in the text in line 203 (page 6): Hepcidin levels are negative correlated to sTfR receptor (mg/l)3 ; Beta -0.62, p=0.041) and positive towards sTfR-index (sTfR(mg/L) /Log ferritin(ug/L)); Beta 8.3, p-value 0.001), table S1.

Potential markers Beta P-value

MCV (fl)1 0.02 0.851

MCH (pg/cells) 1 0.002 0.975

Serum iron (μmol/l) 1 -0.13 0.322

Ferritin (μg/l) 1 0.2 0.538

sTfR receptor (mg/l)3 -0.62 0.041

sTfR index 4 8.3 0.001

sTfR Ratio 4 -2.2 0.310

Table S1. Accuracy of peripheral blood markers in relationship to hepcidin (ng/ml)). Abbreviations: 95%-CI: 95% confidence interval. MCV; mean cellular volume, MCH; mean corpuscular haemoglobin, sTfR: Soluble transferrin receptor, sTfR-index (sTfR (mg/L) /Log ferritin(ug/L)), sTfR Ratio (sTfR(mg/L))x1000/ferritin(ug/L)).1 (29) 2 (11) 3 (29) 4(15, 16)

• For interpretation of the data see point 20.

5\. Ethics Statement: the study does involve human participants -- the authors should therefore add the ethics statement where required.

• Line 158 (page 5) was adjusted. The study was performed with respect of the confidentiality and anonymity of the research participants were participating in the study voluntarily.

6\. Title: The short title is actually more informative than the main title -- suggest using this or similar. (Short title: Difficulties in detection of iron deficiency in severely anaemic HIV-infected patients in Malawi)

• See previous comment 1. Title has been adjusted

7\. Abstract: Line 47 -- although hepcidin and MCV performed best, these are still low AUC-ROC indicating poor performance -- this should be made clear. (e.g. "Although hepcidin and MCV gave the highest AUC-ROC....., all markers performed poorly in identifying BM-ID" or similar). Similar in line 52.

• We appreciate this comment and rephrased Abstract: Line 49-51 and line 54 (page2);

o Line 43-45 (page 2): Although hepcidin and MCV performed best; AUCROC of 0.593 and 0.545, all markers performed poorly in identifying BM-ID (ROC\<0.6). The AUCROC of hepcidin in males was 0.767 (sensitivity 80%, specificity 78%) and in women 0.490 (sensitivity 60%, specificity 61%).

o Line 48-51 (page 2); It remains challenging to accurately assess iron status in severely anaemic HIV-infected patients. Further investigation of the potential of hepcidin is needed, including exploration of the discrepancy in hepcidin results between males and females.

8\. Abstract: Lines 52-54 -- The final line of the conclusion is not fully supported by the data which finds hepcidin to perform poorly overall in identifying BM-ID, albeit slightly less poorly than the other markers (and with moderate performance in males). Furthermore, whether iron supplementation in such settings is curative is controversial (e.g. see recent publication Haider et al, Am J Trop Med Hyg, 2019). This conclusion should be softened, e.g. state that it still remains challenging to accurately assess iron status in HIV using peripheral blood markers / say further investigation of the potential of hepcidin should be performed, especially to confirm the discrepancies between males and females.

• We appreciate the comments of the reviewer and line 53-55 of the abstract has been rephrased (see previous comment 7).

• We have now cited the Haider 2019 reference as suggested by the reviewer in the discussion: Line 307 (page 13): Moreover recently (2019) it has been shown that iron supplementation in a HIV population may be related to increased mortality (45). Therefore a reliable diagnosis of iron deficiency is important, as supplementation could put the patient at risk.

9\. Introduction: Line 62 -- the authors could also point out the risk of iron supplements in areas of high infectious burden (e.g. Sazawal et al, Lancet, 2006; Pasricha et al, BMJ, 2018).

• We appreciate this comment and have adjusted the introduction in line 66 (page3): Secondly although iron deficiency is preventable and treatable iron supplementations has been shown to be a risk factor for infections in areas of high infectious burden (8,9).

10\. Introduction: Line 77 -- reference to the BRINDA work could also be useful here (e.g. Suchdev et al, AJCN, 2017)

• In the introduction we have added a statement about the effect of inflammation on the iron metabolism line 71(page 3): Previous studies therefore concluded that peripheral blood markers of iron status, such as ferritin, might not be reliable without a correction for inflammation (14,15).

11\. Introduction: Line 88 -- it is also essential also to discuss hepcidin suppression during erythropoietic demand or hypoxia (e.g. via erythroferrone), especially here where all patients in the study are severely anaemic. In this section, the authors could also cite other studies/contexts where hepcidin has been investigated as a possible diagnostic for iron deficiency (e.g. ref 34 (Jonker); Pasricha et al, STM, 2014; Pasricha et al, Haematologica, 2011)

• We appreciated this comment and adjusted the introduction in line 83 (page 3): Alternative, in situations where erythropoietin demand and/or hypoxia are present (as in severe anaemia), hepcidin levels are decreased. (17-19). However, hepcidin is also unregulated by inflammation. This may limit its use in settings where infections are common (20). However hepcidin was found to be a potential marker to guide iron therapy in severely anaemic children, because in this population there is diminished up regulation of hepcidin in inflammation and iron deficiency due to an increase of erythropoietin (17). It is important to explore the possible role of hepcidin as possible useful marker in guiding iron therapy in severely anaemic adults.

12\. Methods: Line 115-119 -- sTfR definitions. Ref 16 shows that the Ramco assay is calibrated differently to other sTfR assays. It is essential to give further detail on the choice of cutoff -- the 3.6 mg/L cutoff in 16 is based on a different assay. Furthermore, it is hard to see where the 2.75 mg/L cutoff came from; similarly, the sTfR-index cutoffs are assay dependent. This should be clarified and analyses reperformed as necessary.

• We appreciate and agree with the comments of the reviewer. We have this specific test to determine sTfR to be able to compare this to previous work and since it is a practical assay to perform in a non-high tech environment. As other studies have used different methods, this may have affected the comparability of our results and we have therefor tested several previously published cut-offs and use AUC-ROC curves to identify potential improved cut-offs. As it is confusing that we presented data (table 2) for more cutoffs than we described in the methods section, we have reduced the number of cut offs presented in table 2 We furthermore added the point raised by the reviewer to the discussion:

o Line 218 page 13: We have used a specific test for sTfR to be able to compare this to other work and since it is a practical assay to perform in a non-high tech environment. However other study may have used other tests, which may have affected the comparability of our results. We have therefor tested several previously published cut-offs and use AUC-ROC curves to identify potential improved cut-offs.

• The presented cut-offs used were based on three previous publications. Unfortunately only one was displayed in the method section whilst others were displayed in the footnote of table 2. We have added the footnotes to the methods (line 116 page 4): For sTfR we used 2.7 mg/l and 3.6 mg/l and for the sTfR-index: 1.8 and 2.2, 2.8 respectively, as no international cut-offs have been defined, these represented the most resent consensus (21-23).

13\. Methods: BM-ID. Whether or not blinding was used should be described.

• Line 135 (page 4) of the method was adjusted: The reviewing pathologist was simply provided with the patient's identification number and was not aware of the clinical condition of the patients when reviewing the bone marrow.

14\. Methods/Results: Were any inflammatory markers (e.g. CRP, AGP) assessed or could samples be reanalysed to add this data? These would aid the analysis and its interpretation. Additionally, if samples were still available, measuring erythroferrone (e.g. Intrinsic ELISA) would be very interesting.

• We appreciate the comments of the reviewer and we fully agree with the reviewer. However CRP and erythroferrone values were not determined and samples to perform retesting are not available. We adjusted the limitation section in the discussion to highlight this comment: Line 337 (page 14): Other than the presence of the tested pathogens we did not determine inflammatory markers such as CRP were not available for our patients.

15\. Results: Table 1 / Lines 201-203 -- hepcidin results are presented in ng/mL, yet LOD in methods is given in nmol/L -- the units should be synchronised.

• We are very sorry for this misunderstanding and adjusted the method line 158-1124 (page 4): Hepcidin concentrations are expressed as nanogram per millilitre (ng/mL). The lower limit of detection of this method was 0.5 ng/mL (18).

• We further adjusted this error in the title of figure 1. Figure 1. Hepcidin (ng/mL) ROC curve by gender with optimal cut-off

16\. Results: Table 2 -- hepcidin data should be added to this table for completion - it is not particularly clear linked to Figure 1 (partly due to resolution issues).

• Several adjustments have been made to clarify this point:

o Hepcidin information was moved from figure 1 into table 2.

o The legend for figure 1 was adjusted: Figure 1. Hepcidin (ng/mL) ROC curve by gender with optimal cut-off. The best cut-off value for diagnosing BM-ID, table 1, was determined by the Youden index (maximum (sensitivity + specificity −1)) in the ROC-curve (25). Hepcidin overall; AUCROC 0.593, optimal cut-off ≤7 ng/mL (sensitivity 67% & specificity 67%). Hepcidin in man; AUCROC 0.767 optimal cut-of ≤6 ng/mL (sensitivity 80%; specificity 78%). Hepcidin in women 0.490 optimal cut-off ≤7 ng/ml (sensitivity 60% & specificity 61%. Abbreviations: AUCROC: Area Under Curve of Receiver Operating Characteristic.

17\. Discussion -- line 243/244 -- see point above on abstract-line 47. Suggest changing the emphasis to indicate that they are still generally poor performing tests in this setting -- this raises the question of its suitability for use in this setting.

• We agree with the reviewer and adjusted line 246 (page 12): In the first study evaluating hepcidin as a marker for BM-ID among severely anaemic HIV-infected adults in this setting we found all tested markers performed suboptimal in detecting BM-ID. Hepcidin was the best performing marker but also had a suboptimal accuracy (AUCROC 0.593), which was less pronounced in males (AUCROC 0.767). MCV was found to be the best, suboptimal conventional peripheral blood marker for BM-ID. As the MCV is commonly provided as part of routine full blood counts this marker may be of some use in resource-limited settings.

18\. Discussion -- line 249-250: the authors should add supporting evidence from the literature that ART associates with iron-deficiency (specifically, not just anaemia). As far as we know only ART including Protease Inhibitors (PI) can be associated with iron deficiency directly. As in our study cohorts PI's were not used we prefer not to make a comment on this topic in the current manuscript. Reference: Yusuf E. Afacan Yusuf E. Afacan, Muhammad S. Hasan, and Jackson A. Omene Iron deficiency anemia in HIV infection: immunologic and virologic response. J Natl Med Assoc. 2002 Feb; 94(2): 73--77.

19\. Discussion - line 264, 270, 308-311: attention is drawn to the recently published large study on anaemia and mortality in HAART-treated HIV in which iron supplements during HAART were associated with increased mortality (Haider et al, Am J Trop Med Hyg, 2019). It would be useful to draw this into the discussion.

• We agree with the reviewer and changed the discussion to highlight the results published by Haider et al; see comment 8.

20\. Discussion -- line 273: besides inflammation, the potential involvement of hepcidin suppressive signals during severe anaemia should also be considered (e.g. is there a negative association between hepcidin and sTfR concentrations).

• We appreciate the comment of the reviewer. As raised earlier we have evaluated the association between hepcidin and sTfR concentration with a linear regression model, table 3. See comment 4. The coefficient was indeed negative (-0.11) and reached significance. This may be explained by the fact that inflammation is an important factor upregulating hepcidin, whilst does not affects sTfR levels. Without markers to test for inflammation this remains speculative though. We have included this in the discussion: -- Line 340 (page 14): Hepcidin may be influenced by multiple conflicting stimuli in this patient population including, iron deficiency, anaemia/hypoxia and inflammation. We found an inverse association between hepcidin and sTfR, which may indicate that inflammation was an important stimulus of hepcidin levels in our population. Without in-depth analysis including all relevant stimuli and repeated sampling it is very difficult to understand the complexity of hepcidin and iron metabolism in our population. Low hepcidin values could indicate that iron supplementation would be indicated and effective in reducing anaemia caused by iron deficiency. However the effectiveness and safety should be evaluated in a prospective trial design in this population.

21\. Formatting and spelling

• Formatting / Spelling: Authors: "Dorine Swinkels" (not "Dorien"): This has been corrected

• Formatting / Spelling: Methods -- Statistics: Line 165 -- sentence is unclear ("confounding was enhanced..."): This was rephrased line 165 (page 5): To assess any confounding factors, hepcidin concentrations were evaluated by gender, HIV disease progression, the use of ART as baseline, and TB infection (Pearson Chi-square test).

• Formatting / Spelling: Line 299: "men" and "women". This has been corrected.

• Formatting / Spelling: Reference 37: "Reference values..." This has been corrected.

Reviewer 2

Major comments:

22\. Hepcidin as a serological test to evaluate for iron deficiency is relatively expensive and not readily available compared to other more conventional tests such as complete blood counts (MCV, MCH), ferritin levels, serum iron and even soluble transferrin receptor. Given that hepcidin only marginally performed better than MCV in the AUCROC analysis (0.59 vs 0.55, both low diagnostic accuracy at \<0.7), will the authors strongly recommend this as the best possible peripheral test for evaluation of iron deficiency in HIV infected populations in resource limited settings with high levels of inflammation?

• We fully agree that none of the tested markers were optimal; including hepcidin and that given the current costs hepcidin is of little added value. Since Hepcidin may be predictive of iron supplementation success and safety we believe our results are important. Until this has been proven and when only conventional markers are available, MCV could still be used, We have now clarified this in the text and have also highlighted (with a new reference - Haider 2019), see comment 8 & 19, The importance of avoiding unnecessary iron supplementation in HIV-infected adults.

23\. It is interesting that the prevalence of BM iron deficiency is relatively high in this study population of HIV infected, severely anaemic adults- 48%, similar to the non-HIV infected population and prevention and treatment of iron deficiency still plays a vital role in management of severely anaemic HIV infected patients. Were there other potentially treatable causes of severe anaemia noted by the authors? for example, from the baseline table, the percentage of the study population with high viral loads (\>1000 copies/ml) was very high at 75% and this could have also contributed significantly to anaemia in this population.

• We fully agree with the reviewer's comment. We have submitted a 'back-to-back' manuscript: "Severe anaemia complicating HIV in Malawi; multiple co-existing aetiologies are associated with high mortality" in which we describe the relationship between different anaemia aetiologies in the same patient population and have therefore not repeated these findings in this paper.

24\. Iron supplementation has been found to increase the risk of malaria and other infectious diseases in Malawian HIV infected children from previous randomized controlled trials. Given that iron deficiency strongly contributes to the aetiology of anaemia in this study population of HIV infected adults, how do the authors suggest that this problem (found in nearly half of your study population) be addressed?

• We agree that iron supplementation is not without risk so we do not suggest that all anaemic patients with HIV should start iron supplementations. However, we suggest that there might be a role for hepcidin in the future to guide clinicians about the need for iron supplements. We have adjusted the text to take account of this. See comment 8 &19.

25\. stfr receptor had an AUC of 0.52 (low diagnostic accuracy) but a better sensitivity (71%) than hepcidin (67%) and (MCV 42%) from the findings of this study. would this not be a better screening tool for iron deficiency than hepcidin given the availability and cost? or are the authors going strictly by the AUC, which for both markers (hepcidin and stfr receptor) are equally poor?

• We agree with the reviewer that we may not have highlighted this clearly in our discussion. We have now added the information: line 316 page 13: Although sTfR had a poor AUCROC it did have a better sensitivity than e.g. hepcidin and thus may be used to screen for iron deficiency

Minor comments:

26\. Why are p values provided in table 1? Are the authors trying to tell us that the iron markers, infection rates, HIV tests and nutritional status did not differ significantly in the BM-ID vs non BM-ID group?

• In the method line 195 we state: " Baseline characteristics were compared between BM-ID and non-deficient patients using Chi-square test (dichotomous data) or t-test (continuous) or Pearson Chi-square test (continuous not normally distributed)." As the reviewer has noted, we did this to provide clear data on BM-ID and to understand the relationship between potential confounding factors in the clinical outcome. However we agree this information is not very useful to the reader. We have there for deleted the column and added a footnote: all tested p-values were \> 0.1.

27\. Could the authors offer further explanation as to why the hepcidin test performed better in males than females, with the test over 0.7 in males with sensitivity of 80% and sensitivity of 78% compared with females, with the AUC of \<0.5 with poorer sensitivity and specificity?

• As we described in the discussion, we do not have a good explanation why hepcidin performed better in men as compared to women. Age and gender differences in hepcidin concentrations and thus cut offs to detect ID have been repeatedly reported. As described in the discussion(line 303; page 13), these reference data have detected in European subjects and currently no hepcidin reference levels have been published for an African population. Line 303 (page 13) was rephrased: Therefore a direct comparison is challenging and a clear clarification of the gender differences difficult.

28\. Discussion, line 272, second sentence: \'it is not surprising that hepcidin remains from perfect as a marker for BM-ID" should be changed to 'it is not surprising that hepcidin remains far from perfect as a marker

• Adjusted as requested.

We hope to have clarified outstanding questions and improved the manuscript according to the concerns raised. Please do not hesitate to contact us if you have any further questions.

With many thanks for your consideration, and on behalf of all the authors.

Minke Huibers, MD

###### 

Submitted filename: Respons to reviewers PLOS one manuscript 2.docx

###### 

Click here for additional data file.
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Dear mrs Huibers,

Thank you for submitting your manuscript to PLOS ONE. Both reviewers felt that the revised manuscript is improved. However, reviewer 1 requested some clarifications that require further revision. Therefore, we invite you to submit a new version of the manuscript that addresses the points raised by the reviewer.

We would appreciate receiving your revised manuscript by Dec 07 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Kostas Pantopoulos, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you to the authors for their responses to the first reviews. The manuscript is improved, but some points remain that should be addressed or clarified:

1\. Reviewer response points 1, 8, 24: In the concluding paragraphs of the discussion, the authors discuss how hepcidin might effectively and safely guide iron supplementation. The authors have now mentioned earlier in the discussion, in response to the previous review, that the large Haider et al study provides evidence that iron supplementation associates with increased mortality in anaemic HIV-infected individuals. It would seem appropriate to also mention this caveat, at least as a brief qualifying statement, when safety of iron supplementation is considered at the end of the discussion -- hepcidin may indicate that iron could be absorbed, but would not necessarily mean this was safe.

2\. Reviewer response point 12: It is still not clear how these are consensus cutoffs from these manuscripts (Refs 21 and 22 don't include the RAMCO assay as far as I can see; ferritin index cutoffs are also dependent on which sTfR assay is used). I am not suggesting that the RAMCO assay is an inappropriate choice, but obtaining cutoffs from papers which used different assays is not appropriate when the assays are calibrated differently, unless some conversion is used (e.g. as in Rohner et al, AJCN, 2017). It would seem sufficient to use optimal cutoffs from the AUC-ROC analyses as the authors have done -- I suggest removing reference to a "most recent consensus". Of note, other papers have used a cutoff of 8.3 mg/L with the RAMCO assay (e.g. Rohner et al, AJCN, 2017). I apologise for missing this previously, but could the authors comment on why the sTfR values obtained in this anaemic population seem so much lower than in other studies using this assay (which states normal range 2.9-8.3 mg/L; [www.ramcolab.com](http://www.ramcolab.com)/page13.html)?

3\. Reviewer response point 17: As discussed with the parallel manuscript, the fact that MCV has the highest (or least low) AUC-ROC does not change the fact that it performs poorly as a diagnostic for bone marrow ID in this population. The data presented in the manuscript do not in my view therefore support the view that MCV is useful for assessing iron status in this population (e.g. lines 267-269; 352-355).

4\. General point: attention needs to be given to manuscript organisation and spelling/grammar in places. For example:

• Line 333-335: repetition

• Table S1 (hepcidin not hepcidine)

• Spelling in Ref 42

• Line 260: suboptimally

• Line 346: therefor

Reviewer \#2: question 4: reviewer 1 asked for raw data to be made available as supplementary information for further review, in line with Plos One policy. if possible, the authors should provide an anonymized dataset where necessary for readers who wish to further analyze the data.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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13 Jan 2020

To: PLOS ONE Kostas Pantopoulos, PhD Academic Editor

Subject: Rebuttal letter resubmission Manuscript ID: PONE-D-19-15824

January 2020

Dear Kostas Pantopoulos,

We thank you for accepting our manuscript titled; "Hepcidin and conventional markers to detect iron deficiency in severely anaemic HIV-infected patients in Malawi " with minor changes for publication in your journal. We would like to highlight that we initially submitted two manuscripts back to back. The other manuscript titled; "Severe anaemia complicating HIV in Malawi; multiple co-existing aetiologies are associated with high mortality" (PONE-D-19-15827) has also been resubmitted. Please these below for our responses to issues raised by the reviewer. In our responses below we have indicated the original text (with respective line and page numbers) and changes are underlined. As requested we have tracked change all changes made in the original manuscript.

Responses to reviewer

1\. Reviewer response points 1, 8, 24: In the concluding paragraphs of the discussion, the authors discuss how hepcidin might effectively and safely guide iron supplementation. The authors have now mentioned earlier in the discussion, in response to the previous review, that the large Haider et al study provides evidence that iron supplementation associates with increased mortality in anaemic HIV-infected individuals. It would seem appropriate to also mention this caveat, at least as a brief qualifying statement, when safety of iron supplementation is considered at the end of the discussion -- hepcidin may indicate that iron could be absorbed, but would not necessarily mean this was safe.

• We appreciate the comment of the reviewer and adjusted the following sentence: line 364 (page 17): Low hepcidin values indicate that iron stores are deficient and suggest that iron supplementation will be absorbed. However, the effectiveness and safety should be evaluated in a prospective trial design in this population.

2\. Reviewer response point 12: It is still not clear how these are consensus cut-offs from these manuscripts (Refs 21 and 22 don't include the RAMCO assay as far as I can see; ferritin index cut-offs are also dependent on which sTfR assay is used). I am not suggesting that the RAMCO assay is an inappropriate choice, but obtaining cut-offs from papers, which used different assays, is not appropriate when the assays are calibrated differently, unless some conversion is used (e.g. as in Rohner et al, AJCN, 2017). It would seem sufficient to use optimal cut-offs from the AUC-ROC analyses as the authors have done -- I suggest removing reference to a "most recent consensus". Of note, other papers have used a cutoff of 8.3 mg/L with the RAMCO assay (e.g. Rohner et al, AJCN, 2017). I apologise for missing this previously, but could the authors comment on why the sTfR values obtained in this anaemic population seem so much lower than in other studies using this assay (which states normal range 2.9-8.3 mg/L; [www.ramcolab.com](http://www.ramcolab.com)/page13.html)?

• We agree with the reviewer that there is a poor consensus on sTfR cut-offs, especially if different methods are applied. Although the cut-offs suggested by the assay range from 2.9-8-3, we agree that the most commonly used cut-off of 8.3mg/L should be reported in our manuscript and have added that to the methods section and table 2

• We have removed the statement 'most recent consensus' (page 4, 117) so the text now reads: No international cut-offs have been defined for sTFR or for the sTFR-index so we tested several previously used cut-offs. For sTfR we used 2.7 mg/l, 3.6 mg/l and 8.3 mg/l and for the sTfR-index 1.8, 2.2 and 2.8 repectively (21-23).

• The results in our population were low as mentioned by the reviewer. This may reflect the fact that inflammation, which is associated with low sTfR values, was common in our population (Ferguson et al J Lab Clin Med 1992 and Petterson et al Br J Rheumatol 1994). This corroborates data from Indonesia that reported low sTfR in patients with advanced HIV and further noted that low sTfR levels were associated with a poor outcome (Wisiksana, BMC-ID 2011). As the mortality in our patients was even higher than in this Indonesian study, our values may reflect both inflammation and poor prognosis in our patients. We have highlighted this in the discussion: p16 line 526. Overall sTfR levels in our population were low compared to other studies (49). This may reflect the high prevalence of inflammation and end-stage HIV disease in our population, which are both associated with low sTfR levels (38).

3\. Reviewer response point 17: As discussed with the parallel manuscript, the fact that MCV has the highest (or least low) AUC-ROC does not change the fact that it performs poorly as a diagnostic for bone marrow ID in this population. The data presented in the manuscript do not in my view therefore support the view that MCV is useful for assessing iron status in this population (e.g. lines 267-269; 352-355).

• We agree with the reviewer. As MCV is commonly available and used in low-middle income countries, we feel it should not be omitted from the manuscript. We have changed the text in line with the suggestion of the reviewer

• Line 266-267 (page 14): "MCV was found to be the best suboptimal conventional peripheral blood marker for BM-ID" was deleted

• Line 261 (page 14) :" In the meanwhile, as the MCV is commonly provided as part of routine full blood counts this marker may be of some use in resource-limited settings. ", was deleted.

• 535 (page 16): We have adjusted the text to read, 'The best, though still suboptimal, conventional peripheral blood marker for iron deficiency was MCV. Microcytosis is commonly used as a screening test for deficiency (34, 48); however, MCV has not been found to be an accurate predictor of BM-ID (10, 11, 49). our findings confirm this as MCV did not have a high sensitivity or specificity and the AUCROC was of low diagnostic value'.

4\. General point: attention needs to be given to manuscript organisation and spelling/grammar in places. For example:

• Line 333-335: repetition, corrected

• Table S1 (hepcidin not hepcidine)

• Spelling in Ref 42

• Line 260: suboptimally

• Line 346: therefor

• We have adjusted the spelling/grammar accordingly; moreover we have as suggested by the reviewer reviewed spelling and grammar. The sections have been adjusted as requested and the manuscript has been revised by a native English speaker.

Reviewer \#2: question 4: reviewer 1 asked for raw data to be made available as supplementary information for further review, in line with Plos One policy. if possible, the authors should provide an anonymized dataset where necessary for readers who wish to further analyse the data.

• Data availability: We are very willing to send this reviewer an anonymised database, as well as interested researchers. Therefore we submitted an anonymised database as a supplementary file.

We hope we have clarified outstanding questions and improved the manuscript according to the concerns raised. Please do not hesitate to contact us if you have any further questions.

With many thanks for your consideration, on behalf of all the authors.

Minke Huibers, MD, PhD.

10.1371/journal.pone.0218694.r005
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Dear Dr. Huibers,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Kostas Pantopoulos, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.
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